Journal
PHARMACOLOGY & THERAPEUTICS
Volume 187, Issue -, Pages 13-30Publisher
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.pharmthera.2018.02.001
Keywords
Cancer stem cells; Clinical trial; Tumor initiating cells; Cancer relapse; Targeted therapy; Personalized medicine
Categories
Funding
- Department of Employment and Learning
- BBSRC [BB/I006958/1] Funding Source: UKRI
- MRC [G1001473] Funding Source: UKRI
- Biotechnology and Biological Sciences Research Council [BB/I006958/1] Funding Source: researchfish
- Medical Research Council [G1001473] Funding Source: researchfish
Ask authors/readers for more resources
Resistance to chemotherapy and cancer relapse are major clinical challenges attributed to a sub population of cancer stem cells (CSCs). The concept of CSCs has been the subject of intense research by the oncology community since evidence for their existence was first published over twenty years ago. Emerging data indicates that they are also able to evade novel therapies such as targeted agents, immunotherapies and anti-angiogenics. The inability to appropriately identify and isolate CSCs is a major hindrance to the field and novel technologies are now being utilized. Agents that target CSC-associated cell surface receptors and signaling pathways have generated promising pre-clinical results and are now entering clinical trial. Here we discuss and evaluate current therapeutic strategies to target CSCs. (C) 2018 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available